AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18071056 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (cumulative dose, 0.4 μg/kg)
Number of subjects: 73
Study 18071056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 15910204 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release mixed amphetamine salts (MAS-XR) 10-30 mg doses
Number of subjects: 568
Study 12790363 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) 1000 mg injection
Number of subjects: 30
Study 12790363 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 30
Study 10503804 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded assessment of the Jadad scale
Number of subjects: 76
Study 10503804 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded assessment of the Jadad scale
Number of subjects: 76
Study 10503804 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded assessment with removal of the third item (withdrawals)
Number of subjects: 76
Study 10503804 — intervention group
Group type: COMPARATOR
Intervention: Effect of blinding on Jadad scale scores
Number of subjects: 76
Study 7773118 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers' administration of questionnaires
Number of subjects: 3017
Study 7773118 — intervention group
Group type: COMPARATOR
Intervention: Researchers' administration of questionnaires
Number of subjects: 3017
Study 1972557 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (800 micrograms)
Number of subjects: 8
Study 1972557 — intervention group
Group type: COMPARATOR
Intervention: Inhaled pirbuterol (800 micrograms)
Number of subjects: 8
Study 387057 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-196 (10 mg daily)
Number of subjects: 42
Study 387057 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-196 (15 mg daily)
Number of subjects: 42
Study 387057 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT; 50 mg daily)
Number of subjects: 42
Study 30447510 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents under Pressure (PuP) program
Number of subjects: 115
Study 30447510 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 115
Study 29469081 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 65196
Study 29469081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65196
Study 26503347 — intervention group
Group type: EXPERIMENTAL
Intervention: SoluMatrix meloxicam 5mg
Number of subjects: 0
Study 26503347 — intervention group
Group type: EXPERIMENTAL
Intervention: SoluMatrix meloxicam 10mg
Number of subjects: 0
Study 26503347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23552356 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual melatonin 3 mg
Number of subjects: 60
Study 23552356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20705718 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hCG
Number of subjects: 0
Study 20705718 — intervention group
Group type: COMPARATOR
Intervention: rFSH plus GnRH antagonist
Number of subjects: 0
Study 19930615 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience training program (READY) with physical activity promotion
Number of subjects: 95
Study 19930615 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience training program (READY) without physical activity promotion
Number of subjects: 95
Study 19930615 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 95
Study 16814744 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 90
Study 16814744 — intervention group
Group type: COMPARATOR
Intervention: Control program (placebo)
Number of subjects: 90
Study 15257812 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 0.1 mg (group 1)
Number of subjects: 0
Study 15257812 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 0.1 mg (group 2)
Number of subjects: 0
Study 15257812 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 0.5 mg (group 3)
Number of subjects: 0
Study 15257812 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 0.1 mg three times (group 4)
Number of subjects: 0
Study 15257812 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (group 5)
Number of subjects: 0
Study 15257812 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotrophin (HCG) 1500 IU (group 6)
Number of subjects: 0
Study 11166518 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (APO), 0.01 mg/kg
Number of subjects: 98
Study 11166518 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic drug treatment
Number of subjects: 98
Study 9154767 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg orally once per day for four weeks)
Number of subjects: 57
Study 9154767 — intervention group
Group type: COMPARATOR
Intervention: Placebo (orally once per day for four weeks)
Number of subjects: 57
Study 9154767 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 57
Study 8227504 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician administered treatment
Number of subjects: 12
Study 8227504 — intervention group
Group type: COMPARATOR
Intervention: Combination of clinician administered treatment and parent administered instruction with the Speech Viewer system
Number of subjects: 12
Study 2900682 — intervention group
Group type: EXPERIMENTAL
Intervention: progabide
Number of subjects: 33
Study 2900682 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study 29532525 — intervention group
Group type: EXPERIMENTAL
Intervention: Deproteinized bone mineral with a collagen membrane
Number of subjects: 27
Study 29532525 — intervention group
Group type: COMPARATOR
Intervention: Collagen membrane only
Number of subjects: 27
Study 27397824 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led cognitive-behavioral intervention program (12 weeks)
Number of subjects: 100
Study 27397824 — intervention group
Group type: COMPARATOR
Intervention: Traditional care (control group)
Number of subjects: 100
Study 24602844 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antiretroviral treatment
Number of subjects: 1763
Study 24602844 — intervention group
Group type: COMPARATOR
Intervention: Delayed antiretroviral treatment
Number of subjects: 1763
Study 22949223 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (ABA)
Number of subjects: 99
Study 22949223 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 99
Study 22949223 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 99
Study 20493485 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) insufflation
Number of subjects: 74
Study 20493485 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 74
Study 17766190 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous meropenem (120 mg/kg/day) and intravenous tobramycin (9-12 mg/kg/day)
Number of subjects: 118
Study 17766190 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftazidime (200-400 mg/kg/day) and intravenous tobramycin (9-12 mg/kg/day)
Number of subjects: 118
Study 16741879 — intervention group
Group type: EXPERIMENTAL
Intervention: ART
Number of subjects: 116
Study 16741879 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CD4+ and CD8+ T cell activation
Number of subjects: 116
Study 16741879 — intervention group
Group type: EXPERIMENTAL
Intervention: High memory (CDRA(‐)CD62L‐) CD8+ T cell counts at baseline
Number of subjects: 116
Study 16741879 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased naive CD4+ T cell counts
Number of subjects: 116
Study 16741879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-associated HIV-1 DNA level at baseline
Number of subjects: 116
Study 16741879 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-associated HIV-1 DNA level at week 48 of ART
Number of subjects: 116
Study 12826839 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotrend monitoring
Number of subjects: 120
Study 12826839 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 120
Study 12826839 — intervention group
Group type: COMPARATOR
Intervention: Standard anesthetic practice
Number of subjects: 120
Study 10813122 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ultrasonography
Number of subjects: 77
Study 10813122 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative ultrasonography with bimanual liver palpation
Number of subjects: 77
Study 10813122 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced computerized tomography (CT)
Number of subjects: 77
Study 8978441 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult mental calculation task
Number of subjects: 0
Study 8978441 — intervention group
Group type: EXPERIMENTAL
Intervention: Sternberg paradigm with a memory set of 5 or 3 digits
Number of subjects: 0
Study 8978441 — intervention group
Group type: COMPARATOR
Intervention: Control stimulus with the same physical characteristics as the arithmetical symbols
Number of subjects: 0
Study 1452593 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction therapy using videos during burn dressing changes
Number of subjects: 17
Study 6711270 — intervention group
Group type: COMPARATOR
Intervention: 40 ml of 1% mepivacaine with adrenaline 1:200,000
Number of subjects: 90
Study 6711270 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ml of 1% mepivacaine with adrenaline 1:200,000
Number of subjects: 90
Study 6711270 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 ml of 1% mepivacaine with adrenaline 1:200,000
Number of subjects: 90
Study 31204396 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-ionomer sealants with acid pretreatment
Number of subjects: 90
Study 31204396 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based sealants with acid pretreatment
Number of subjects: 90
Study 31204396 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth treated with air abrasion and acid etching
Number of subjects: 90
Study 31204396 — intervention group
Group type: EXPERIMENTAL
Intervention: Fissure depth
Number of subjects: 90
Study 31204396 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel surface preparation protocols
Number of subjects: 90
Study 29855172 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-122 60 mg every other week
Number of subjects: 222
Study 29855172 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-122 120 mg every other week
Number of subjects: 222
Study 29855172 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-122 120 mg every week
Number of subjects: 222
Study 29855172 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg every other week
Number of subjects: 222
Study 26350429 — intervention group
Group type: EXPERIMENTAL
Intervention: Print educational intervention
Number of subjects: 103
Study 26350429 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital educational intervention
Number of subjects: 103
Study 23689963 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-stabilized TKA
Number of subjects: 40
Study 23689963 — intervention group
Group type: COMPARATOR
Intervention: Cruciate-retaining TKA
Number of subjects: 40
Study 22750961 — intervention group
Group type: EXPERIMENTAL
Intervention: SaeboFlex orthosis training for 1 hour per day, 5 times per week for 4 weeks
Number of subjects: 10
Study 22750961 — intervention group
Group type: COMPARATOR
Intervention: SaeboFlex orthosis (control group) for 1 hour per day without training
Number of subjects: 10
Study 22750961 — intervention group
Group type: EXPERIMENTAL
Intervention: SaeboFlex orthosis training
Number of subjects: 10
Study 19347946 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed CO2 laser at 9.3 μm, 25 or 50 Hz, 20 J/cm2 for 3,000 pulses (36 J) with water cooling
Number of subjects: 29
Study 19347946 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed CO2 laser at 9.3 μm, 25 or 50 Hz, 20 J/cm2 for 3,000 pulses (36 J) without water cooling
Number of subjects: 29
Study 19347946 — intervention group
Group type: COMPARATOR
Intervention: Control group with no treatment
Number of subjects: 29
Study 19347946 — intervention group
Group type: COMPARATOR
Intervention: Control group with a small cut made with a conventional high-speed hand-piece
Number of subjects: 29
Study 17488511 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) in addition to managed care, consisting of three to six individual sessions of 30 minutes each.
Number of subjects: 194
Study 17488511 — intervention group
Group type: COMPARATOR
Intervention: Managed care only (Control group).
Number of subjects: 194
Study 17488511 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) in addition to managed care.
Number of subjects: 194
Study 15036181 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-transducer ultrasound technique measuring mean ultrasound propagation speed of the cortical and cancellous layers at the tibia shaft.
Number of subjects: 18
Study 11641740 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil-based diet (RO)
Number of subjects: 19
Study 11641740 — intervention group
Group type: COMPARATOR
Intervention: Control diet (SAT)
Number of subjects: 19
Study 9533384 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless learning method
Number of subjects: 0
Study 9533384 — intervention group
Group type: COMPARATOR
Intervention: Errorful learning method
Number of subjects: 0
Study 8304656 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective digestive decontamination using polymyxin E, tobramycin, and amphotericin B
Number of subjects: 80
Study 8304656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 8304656 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective digestive decontamination
Number of subjects: 80
Study 2707527 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone intravenous (HC i.v.: 100 mg)
Number of subjects: 17
Study 2707527 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone local (HC L: 100 mg)
Number of subjects: 17
Study 2707527 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA: 4 g)
Number of subjects: 17
Study 2707527 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (S: 1 g)
Number of subjects: 17
Study 29382794 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet CPAP
Number of subjects: 16
Study 29382794 — intervention group
Group type: COMPARATOR
Intervention: Nasal Prong CPAP
Number of subjects: 16
Study 27056648 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 15mg for 5 days
Number of subjects: 51
Study 27056648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 25593103 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine in Arm A (90% of participating girls and boys)
Number of subjects: 32175
Study 25593103 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine in Arm B (90% of girls) and HBV vaccine for boys
Number of subjects: 32175
Study 25593103 — intervention group
Group type: COMPARATOR
Intervention: HBV vaccine in Arm C (all participants)
Number of subjects: 32175
Study 23594918 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norms marketing campaign
Number of subjects: 3800
Study 23594918 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3800
Study 20724955 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of hepatitis B vaccine
Number of subjects: 1478
Study 20724955 — intervention group
Group type: COMPARATOR
Intervention: Preimmunization
Number of subjects: 1478
Study 18543105 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in parental responsiveness, developmental knowledge, and loving touch
Number of subjects: 0
Study 15936605 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 50 microg/kg/min
Number of subjects: 2118
Study 15936605 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 70 microg/kg/min
Number of subjects: 2118
Study 15936605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2118
Study 15936605 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled adenosine group
Number of subjects: 2118
Study 12749125 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 cream
Number of subjects: 42
Study 10582989 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator
Number of subjects: 615
Study 10582989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study 10582989 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 615
Study 8572357 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg.kg‐1 given 2 min before desflurane increase
Number of subjects: 5
Study 8572357 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg.kg‐1 given 5 min before desflurane increase
Number of subjects: 5
Study 8572357 — intervention group
Group type: COMPARATOR
Intervention: No propofol pretreatment
Number of subjects: 5
Study 1656853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazobactam (500 mg) administered alone
Number of subjects: 6
Study 1656853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazobactam (500 mg) coadministered with piperacillin (4 g)
Number of subjects: 6
Study 6799266 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptin (30-40 mg daily)
Number of subjects: 40
Study 6799266 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptin
Number of subjects: 40
Study 31086222 — intervention group
Group type: EXPERIMENTAL
Intervention: Iranian propolis (1000 mg/day)
Number of subjects: 94
Study 28484908 — intervention group
Group type: EXPERIMENTAL
Intervention: TT technique (group A)
Number of subjects: 40
Study 28484908 — intervention group
Group type: EXPERIMENTAL
Intervention: OI technique (group B)
Number of subjects: 40
Study 28484908 — intervention group
Group type: COMPARATOR
Intervention: Control (group A)
Number of subjects: 40
Study 28484908 — intervention group
Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 40
Study 25491475 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar resectoscope
Number of subjects: 70
Study 25491475 — intervention group
Group type: COMPARATOR
Intervention: Bipolar resectoscope
Number of subjects: 70
Study 25491475 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 23813419 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial submandibular gland (SMG) transplantation
Number of subjects: 39
Study 23813419 — intervention group
Group type: COMPARATOR
Intervention: Total submandibular gland (SMG) transplantation
Number of subjects: 39
Study 21114416 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleglitazar 300 μg
Number of subjects: 44
Study 21114416 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg
Number of subjects: 44
Study 21114416 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 40 mg
Number of subjects: 44
Study 19181690 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad mood and activation of old age schema
Number of subjects: 71
Study 19181690 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sad mood and old age schema
Number of subjects: 71
Study 16000582 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour infusion of 100 mg/m2 paclitaxel (Taxol)
Number of subjects: 24
Study 16000582 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour infusion of 100 mg/m2 paclitaxel (Taxol)
Number of subjects: 24
Study 16000582 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel exposure
Number of subjects: 24
Study 14519751 — intervention group
Group type: EXPERIMENTAL
Intervention: MVP group (mitomycin C 8 mg/m2 on day 1, vindesine 3 mg/m2 on days 1 and 8, cisplatin 100 mg/m2 on day 1 every 3 weeks for three cycles)
Number of subjects: 1209
Study 14519751 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 1209
Study 10657575 — intervention group
Group type: EXPERIMENTAL
Intervention: Omacor (4 capsules daily providing 3.4 g EPA+DHA per day)
Number of subjects: 14
Study 10657575 — intervention group
Group type: EXPERIMENTAL
Intervention: Omacor
Number of subjects: 14
Study 10657575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8866593 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 26
Study 8866593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 2071554 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (100 mg po bid for adults and 50 mg po bid for children)
Number of subjects: 190
Study 6219074 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% thymoxamine
Number of subjects: 25
Study 6219074 — intervention group
Group type: COMPARATOR
Intervention: 1% epinephrine
Number of subjects: 25
Study 31643128 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective opioid reduction intervention (discharge sheet, nursing education, standardized prescribing guideline)
Number of subjects: 443
Study 31643128 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective opioid reduction intervention
Number of subjects: 443
Study 31643128 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Intervention cohort
Number of subjects: 443
Study 31251545 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdermal injection
Number of subjects: 36
Study 31251545 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraperiosteal injection
Number of subjects: 36
Study 29379800 — intervention group
Group type: COMPARATOR
Intervention: AIC group
Number of subjects: 10
Study 29379800 — intervention group
Group type: EXPERIMENTAL
Intervention: LRCP+BFSC group
Number of subjects: 10
Study 29379800 — intervention group
Group type: EXPERIMENTAL
Intervention: AIC+BFSC group
Number of subjects: 10
Study 25786679 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with 20 ml bupivacaine 0.25% with adrenaline 5 μg/ml bilaterally
Number of subjects: 60
Study 25786679 — intervention group
Group type: COMPARATOR
Intervention: Control group with normal saline 20 ml bilaterally in the TAP
Number of subjects: 60
Study 25786679 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 60
Study 25786679 — intervention group
Group type: COMPARATOR
Intervention: Control group with wound infiltration
Number of subjects: 60